AWM
MRNA icon

Avitas Wealth Management’s Moderna MRNA Stock Holding History

Avitas Wealth Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,716
Closed -$208K – 209
2023
Q2 		$208K Sell
1,716
-32
-2% -$4.27K 0.04% 195
2023
Q1 		$268K Sell
1,748
-58
-3% -$9.57K 0.05% 187
2022
Q4 		$324K Buy
1,806
+2
+0.1% +$327 0.07% 167
2022
Q3 		$213K Sell
1,804
-638
-26% -$96.8K 0.05% 177
2022
Q2 		$349K Sell
2,442
-786
-24% -$112K 0.08% 161
2022
Q1 		$556K Sell
3,228
-866
-21% -$146K 0.1% 153
2021
Q4 		$1.04M Buy
4,094
+151
+4% +$44.1K 0.17% 124
2021
Q3 		$1.52M Sell
3,943
-1,600
-29% -$590K 0.28% 114
2021
Q2 		$1.3M Sell
5,543
-2,299
-29% -$411K 0.23% 124
2021
Q1 		$1.03M Sell
7,842
-8,247
-51% -$1.2M 0.2% 136
2020
Q4 		$1.68M Sell
16,089
-826
-5% -$83.6K 0.34% 116
2020
Q3 		$1.2M Buy
16,915
+4,478
+36% +$312K 0.33% 105
2020
Q2 		$799K Buy
12,437
+12
+0.1% +$657 0.27% 111
2020
Q1 		$372K Buy
+12,425
New +$286K 0.17% 110

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Avitas Wealth Management's MRNA Position: Q3 2023 in Review

Avitas Wealth Management sold out of Moderna (MRNA) in Q3 2023, closing a stake of 1,716 shares — an estimated $208K sold.

Avitas Wealth Management first reported a position in MRNA in Q1 2020 and held it in 14 quarters. The position peaked at $1.68M in Q4 2020. 889 funds tracked by Wall St. Rank hold MRNA as of Q3 2023.

  • Avitas Wealth Management reported no remaining Moderna position as of Q3 2023 after selling out during the quarter.
  • Avitas Wealth Management sold 1,716 Moderna shares in Q3 2023, an estimated $208K.
  • Avitas Wealth Management first reported a position in Moderna in Q1 2020 and held it in 14 quarters.
  • Avitas Wealth Management's Moderna position peaked at $1.68M in Q4 2020.
  • 889 funds tracked by Wall St. Rank held Moderna as of Q3 2023.

Based on Avitas Wealth Management's 13F filing for Q3 2023, filed 2 Nov 2023.